A meta-analysis of eight randomised trials in 812 menopausal women found melatonin, at doses of 1 mg to 5 mg for 3 to 12 months, modestly improved physical symptoms but did not improve sleep quality, overall menopausal symptoms, mood, anxiety or depression.
What it shows: Meta-analysis of only eight RCTs with varying doses (1-5 mg) and durations (3-12 months); heterogeneity was high for several outcomes and the authors call for larger trials to confirm the findings.Meta-analysis · Menopause